As demand for weight-loss medications like Wegovy (semaglutide) and Zepbound (tirzepatide) skyrockets, a growing number of Americans are bypassing traditional healthcare systems and turning…
More than 70 million American adults—equally split between 35 million men and 35 million women—are classified as obese. Additionally, 99…
In the world of modern healthcare, there’s a new term that’s creating waves: Diabesity. Coined to capture the dual epidemic…
Retatrutide is a promising experimental weight loss drug under development by Eli Lilly. Known as the “Triple G” drug, it…
Liver disease, especially metabolic dysfunction-associated steatohepatitis (MASH), has long been a silent threat, affecting millions of people globally. Often progressing…
GLORY-1 is an innovative investigational therapy in the field of metabolic health, designed as a dual receptor agonist targeting both…
A landmark Phase 3 clinical study of mazdutide, the world’s first dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, has been…
